Evidence map›Paper›PMID 38820313›Full record

ArticlePloS one2024

The MISOPRED score: Development and validation of a clinical scoring system to predict the effectiveness of Misoprostol treatment for early pregnancy loss.

Tomer Bar-Noy, Ofer Limonad, Erika Gandelsman, Alon Shrim, Hila Sharabi, Raphy Zarecki, Mordechai Hallak, Ilan Bruchim

Abstract readValidation Study
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tomer Bar-NoyDepartment of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.ORCID 0000-0003-4605-5552
Ofer LimonadDepartment of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.
Erika GandelsmanDepartment of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.ORCID 0000-0002-9197-645X
Alon ShrimDepartment of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.
Hila SharabiDepartment of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.
Raphy ZareckiSchool of Computer Sciences, Tel Aviv University, Tel Aviv, Israel.
Mordechai HallakDepartment of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.
Ilan BruchimDepartment of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMisoprostol treatment for early pregnancy loss has varied success demonstrated in previous studies. Incorporating predictors in a single clinical scoring system would be highly beneficial in clinical practice.

objectiveTo develop and evaluate the accuracy of a scoring system to predict misoprostol treatment outcomes for managing early pregnancy loss. STUDY

designRetrospective cohort and validation study.

methodsPatients discharged from the gynecologic emergency department from 2013 to 2016, diagnosed with early pregnancy loss, who were treated with 800 mcg misoprostol, administrated vaginally were included. All were sonographically reevaluated within 48-72 hours. Patients in whom the gestational sac was not expelled or with endometrial lining >30 mm were offered a repeat dose and returned for reevaluation after seven days. A successful response was defined as complete expulsion. Clinical data were reviewed to identify predictors for successful responses. The scoring system was then retrospectively evaluated on a second cohort to evaluate its accuracy. Multivariate logistic regression was performed to identify factors most predictive of treatment response.

resultsThe development cohort included 126 patients. Six factors were found to be most predictive of misoprostol treatment effectiveness: nulliparity, prior complete spontaneous abortion, gestational age, vaginal bleeding, abdominal pain, and mean sac diameter, yielding a score of 0-8 (the MISOPRED score), where 8 represents the highest-likelihood of success. The score was validated retrospectively with 119 participants. Successful response in the group with the lowest likelihood score (score 0-3) was 9%, compared with 82% in the highest likelihood score group (score 7-8). Using the MISOPRED score, approximately 15% of patients previously planned to receive misoprostol treatment can be referred for surgical management.

conclusionsMISOPRED score can be utilized as an adjunct tool for clinical decision-making in cases of Early pregnancy loss. To our knowledge, this is the first scoring system suggested to predict the success rate in these cases.

Indexed as

Abortifacient Agents, NonsteroidalAbortion, SpontaneousMisoprostolAdultFemaleHumansPregnancyRetrospective StudiesTreatment OutcomeAbortifacient Agents, NonsteroidalMisoprostol

Identifiers

PMID38820313
PMCPMC11142502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.